The pharmaceutical market in the Philippines is set to experience a moderate rise from $3.4 billion in 2015 to $4.1 billion by 2020, at a compound annual growth rate of 3.7%, according to research and consulting firm GlobalData. The company’s latest report states that the Filipino pharmaceutical market, which is the third-largest in the Association of Southeast…
AF Market Trends: Major Unmet Need for Safer Antiarrhythmic Drugs
While the overall level of unmet need in the atrial fibrillation market is generally considered moderate, the need for safer antiarrhythmic drugs for the maintenance of sinus rhythm is still a major issue in the treatment space, according to research and consulting firm GlobalData. The company’s report states that despite the restoration and maintenance of…
2020 Forecast: Turkey’s Pharma Industry to Hit $5.53B
The pharmaceutical market in Turkey is set to rise from $5 billion in 2015 to $5.53 billion by 2020, representing a compound annual growth rate of 2%, according to research and consulting firm GlobalData. The company’s latest report states that Turkey’s pharmaceutical market has changed extensively over the past decade due to the Health Transformation…
VTE Therapeutics Market Set to Hit $3.7 Billion by 2025
The therapeutics market for venous thromboembolism (VTE), a condition which comprises deep vein thrombosis and pulmonary embolism, is set to rise from $2.8 billion in 2015 to $3.7 billion by 2025, representing a Compound Annual Growth Rate (CAGR) of 2.89 percent, according to research and consulting firm GlobalData. The company’s latest report* states that this…
Vietnamese Pharmaceutical Market to Reach $6.6 Billion by 2020
The pharmaceutical market in Vietnam will expand in value from $3.5 billion in 2015 to an estimated $6.6 billion by 2020, registering a compound annual growth rate of 13.8%, according to research and consulting firm GlobalData. The company’s latest report* states that the increasing elderly population, widespread preference for imported branded drugs, rising government support…
Pharma Licensing Deals Reached $46.2B in 2015
Licensing deal values in the pharmaceutical industry rose by 37.1 percent year-to-year, from $33.7 billion in 2014 to $46.2 billion in 2015, driven primarily by Sanofi, which struck three licensing deals that totaled nearly $9 billion, according to research and consulting firm GlobalData. Gianfranco Zeppetelli, GlobalData’s Deals Analyst, explains: “Sanofi inked two key partnerships for…
Type 2 Diabetes Market Expected to Double by 2025
The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%, according to research and consulting firm GlobalData. The company’s latest report* states that this growth, which will occur across the nine major markets of the US,…
Pfizer & Anacor Merger Set to Leverage Companies in Atopic Dermatitis Space
An upcoming merger agreement between Pfizer and Anacor, worth around $5.2 billion, could boost the marketing power of Anacor’s lead pipeline candidate, crisaborole, and pave the way for Pfizer to launch its own candidate, a topical form of Xeljanz, both for the treatment of mild-to-moderate atopic dermatitis, according to an analyst with research and consulting…
Merck KGaA and Pfizer’s Drug to Be Integral in RCC Treatment
Disease-Modifying Drugs to Propel Huntington’s Disease Market to $2.6B
The Huntington’s disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate (CAGR) of 25.6%, according to research and consulting firm GlobalData. The company’s latest report* states that the main driver of this extensive growth, which will occur across the seven major…
Eli Lilly’s Taltz Could Achieve Blockbuster Status
Eli Lilly’s drug Taltz (ixekizumab), which was recently approved by the FDA for the treatment of adults with moderate-to-severe plaque psoriasis, is set to generate sales in excess of $1 billion in the U.S. and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and…
Heart Failure Market to Reach $11.8 Billion by 2025
LONDON, UK – The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7 percent, according to research and consulting firm GlobalData. The company’s latest report* states that the key drivers of this substantial growth, which will occur across the…
Gilead’s Hand in the HIV Market
The recent FDA approval of Gilead Sciences’ drug Descovy (emtricitabine/tenofovir alafenamide [TAF]) in the treatment of human immunodeficiency virus (HIV) will boost the company’s TAF-based HIV portfolio and allow Gilead to stay on top of a fast-changing treatment landscape, according to an analyst with research and consulting firm GlobalData. As explored in GlobalData’s most recent HIV…
Blockbuster Drugs to Drive Immuno-Oncology Market
The total immuno-oncology market will be worth approximately $14 billion by 2019, rising to $34 billion by 2024, as the treatment of cancer patients undergoes drastic changes over the next decade, according to research and consulting firm GlobalData. The company’s latest report* states that the approval and uptake of immuno-oncology products is set to burgeon…
Psoriasis Market Expected to Double by 2024
The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3 percent, according to research and consulting firm GlobalData. The company’s latest report* states that this impressive growth will be driven by the launch of novel psoriasis products, uptake of…
Opportunities to Manufacture Premium-Priced TKIs for PAH
The Pulmonary Arterial Hypertension (PAH) space, which is currently burdened by significant unmet need, could benefit substantially from a class of drugs known as Tyrosine Kinase Inhibitors (TKIs), which may aid development of a disease-modifying drug, according to an analyst with research and consulting firm GlobalData. Currently, there are 12 marketed therapies for the treatment…
Sobi/Biogen & CSL Behring: Poised for Battle in Hemophilia B Market
GlaxoSmithKline’s MenB Vaccine: Might See Uptake in UK
The UK Department of Health’s rejection of an 800,000-signature public petition to expand the routine administration of the only approved vaccine to offer protection against invasive meningococcal disease (IMD) caused by serogroup B (MenB), may lead to parents and physicians to consider purchasing the vaccine themselves, according to an analyst with research and consulting firm…
Merck & TissueGene’s Drugs to Change Osteoarthritis Market
Anticoagulant Trends in VTE Treatment Market
Indonesia’s Pharma Market: 2020 Predictions
Hepatitis C Market: Merck & Gilead Compete for Dominance
The introduction of Merck and Co.’s recently-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market long-dominated by Gilead. The combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake, says an analyst with research and consulting firm GlobalData. Clinical trial…
Boehringer Ingelheim’s Drug to Gain Ground in NSCLC Markets
Promising recent clinical trial data for Boehringer Ingelheim’s tyrosine kinase inhibitor (TKI) Gilotrif (afatinib) will strengthen the drug’s position in non-small cell lung cancer (NSCLC) treatment markets outside the U.S., says an analyst with research and consulting firm GlobalData. The LUX-Lung 7 trial showed Gilotrif to reduce the risk of adenocarcinoma progression for patients with…
Head & Neck Cancer Market Will Quadruple by 2024
The treatment market for head and neck squamous cell carcinoma (head and neck cancer) will expand almost fourfold from $386 million in 2014 to $1.53 billion by 2024, representing a strong Compound Annual Growth Rate (CAGR) of 14.8%, according to research and consulting firm GlobalData. The company’s latest report* states that the major drivers of…
The Factors Inhibiting Hepatitis B Market Growth
The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research and consulting firm GlobalData. The company’s report* identifies a number of factors that negatively impact hepatitis B treatment…